Zurig 40 Tablet contains Febuxostat 40 mg, a xanthine oxidase inhibitor indicated for the management of hyperuricemia in patients with gout. Febuxostat works by selectively inhibiting xanthine oxidase, an enzyme responsible for the conversion of hypoxanthine to xanthine and subsequently to uric acid, thereby reducing serum uric acid levels. This reduction helps prevent gout flares and the formation of urate crystals in joints and tissues. Zurig 40 is typically prescribed for patients who are intolerant to or inadequately managed by other urate-lowering therapies such as allopurinol. The tablet should be taken orally, with or without food, as directed by a healthcare professional. Dose adjustments may be necessary based on renal or hepatic function and patient response. Common adverse effects include liver function abnormalities, rash, nausea, and joint pain, while serious hypersensitivity reactions are rare but require immediate medical attention. Regular monitoring of serum uric acid levels and liver function tests is recommended during treatment. Zurig 40 should be used cautiously in patients with cardiovascular disease, and concomitant use with azathioprine or mercaptopurine is contraindicated due to potential drug interactions. This medication is intended for use under medical supervision to ensure efficacy and safety.